For everyone, everywhere
Led by the brightest minds in the industry
atai is home to some of the most sought-after executives and scientists in the space. Equipped with a diverse and dedicated team, we are making a concerted effort to redefine mental health paradigms.
Guided by a noble mission
We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
Our unique operating model
Our approach combines funding, access to accelerative platform technologies, as well as scientific and regulatory expertise with a singular focus on developing more rapid-acting and potentially disease-modifying mental health treatments.
Shortcomings of existing therapies
Current standard of care treatments are ineffective for millions worldwide.
Global population with mental health disorders
Of US population impacted
Expected that more than half of US population will have a mental health disorder at some point in their lifetime
Global economic impact
Estimated global economic costs of mental health disorders by 2030
Recent impact of COVID-19
Percentage of US adults experiencing symptoms of depression and anxiety rose from 11% in 2019 to 42% end of 2020
Urgent need for innovation
A third of patients with depression respond inadequately or relapse with current treatments within certain indications
Slow onset of treatment effect
Frontline treatments for depression and anxiety have slow onset (4-12w)
Most of the patients treated for opioid use disorder (OUD) relapse
Psychiatry approvals since 2015
Only 17 new drugs approved by the FDA for psychiatry disorders since 2015 – less than 20% relative to oncology (N=107)
Our unique approach
Compounds with prior evidence in humans
To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.
Enabling platform technologies
Decentralized drug development
In addition to funding, our evolving companies have access to our deep domain expertise and operational backbone.
WHERE WE’RE HEADED
Our technologies drive efficient drug discovery and improved treatment outcomes.
Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics.OUR MODEL
News & Insights
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics…
atai Life Sciences to Participate in September Investor Events
NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical…
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
– Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution…